Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 23:10:1977.
doi: 10.3389/fmicb.2019.01977. eCollection 2019.

Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease

Affiliations

Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease

Jianhui Chen et al. Front Microbiol. .

Abstract

Treatment of Mycobacterium abscessus pulmonary infection requires long-term administration of multiple antibiotics. Little is known, however, about the impact of each antibiotic on treatment outcomes. A retrospective analysis was conducted to evaluate the efficacy and adverse effects of antibiotics administered in 244 cases of M. abscessus pulmonary disease. Only 110 (45.1%) patients met the criteria for treatment success. The efficacy of treating M. abscessus pulmonary disease continues to be unsatisfactory especially for infections involving M. abscessus subsp. abscessus. Treatment with drug combinations that included amikacin [adjusted odds ratio (AOR), 3.275; 95% confidence interval (CI), 1.221-8.788], imipenem (AOR, 2.078; 95% CI, 1.151-3.753), linezolid (AOR, 2.231; 95% CI, 1.078-4.616), or tigecycline (AOR, 2.040; 95% CI, 1.079-3.857) was successful. Adverse side effects affected the majority of patients (192/244, 78.7%). Severe effects that resulted in treatment modification included: gastrointestinal distress (29/60, 48.3%) mostly caused by tigecycline, ototoxicity (14/60, 23.3%) caused by amikacin; and myelosuppression (6/60, 10%) caused mainly by linezolid. In conclusion, the success rate of treatment of M. abscessus pulmonary disease is still unsatisfactory. The administration of amikacin, imipenem, linezolid, and tigecycline correlated with increased treatment success. Adverse side effects are common due to long-term, combination antibiotic therapy. Ototoxicity, gastrointestinal distress, and myelosuppression are the most severe.

Keywords: Mycobacterium abscessus; adverse effect; drug; efficacy; pulmonary disease.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Flow diagram of the study. Two hundred forty-four pulmonary disease patients, who conformed to the inclusion criteria, were enrolled. One hundred eighty-five patients were infected with M. abscessus subsp. abscessus; 59 patients were infected with M. abscessus subsp. massiliense.

Similar articles

Cited by

References

    1. Chen J., Zhao L., Mao Y., Ye M., Guo Q., Zhang Y., et al. (2019). Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease. BioRxiv - PMC - PubMed
    1. Chua K. Y., Bustamante A., Jelfs P., Chen S. C., Sintchenko V. (2015). Antibiotic susceptibility of diverse Mycobacterium abscessus complex strains in new South Wales, Australia. Pathology 47 678–682. 10.1097/PAT.0000000000000327 - DOI - PubMed
    1. Griffith D. E. (2019). Mycobacterium abscessus and antibiotic resistance: same as it ever was. Clin. Infect. Dis. 10.1093/cid/ciz071 [Epub ahead of print]. - DOI - PubMed
    1. Griffith D. E., Aksamit T., Brown-Elliott B. A., Catanzaro A., Daley C., Gordin F., et al. (2007). An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175 367–416. 10.1164/rccm.200604-571ST - DOI - PubMed
    1. Guo Q., Chu H., Ye M., Zhang Z., Li B., Yang S., et al. (2018). The Clarithromycin susceptibility genotype affects the treatment outcome of patients with Mycobacterium abscessus lung disease. Antimicrob. Agents Chemother. 62:e2360-17. 10.1128/AAC.02360-2317 - DOI - PMC - PubMed